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Abstract
Fragile site breakage was previously shown to result in rearrangement of the RET oncogene, resembling the
rearrangements found in thyroid cancer. Common fragile sites are specific regions of the genome with a high
susceptibility to DNA breakage under conditions that partially inhibit DNA replication, and often coincide with genes
deleted, amplified, or rearranged in cancer. While a substantial amount of work has been performed investigating
DNA repair and cell cycle checkpoint proteins vital for maintaining stability at fragile sites, little is known about the
initial events leading to DNA breakage at these sites. The purpose of this study was to investigate these initial events
through the detection of aphidicolin (APH)-induced DNA breakage within the RET oncogene, in which 144 APH-
induced DNA breakpoints were mapped on the nucleotide level in human thyroid cells within intron 11 of RET, the
breakpoint cluster region found in patients. These breakpoints were located at or near DNA topoisomerase I and/or II
predicted cleavage sites, as well as at DNA secondary structural features recognized and preferentially cleaved by
DNA topoisomerases I and II. Co-treatment of thyroid cells with APH and the topoisomerase catalytic inhibitors,
betulinic acid and merbarone, significantly decreased APH-induced fragile site breakage within RET intron 11 and
within the common fragile site FRA3B. These data demonstrate that DNA topoisomerases I and II are involved in
initiating APH-induced common fragile site breakage at RET, and may engage the recognition of DNA secondary
structures formed during perturbed DNA replication.
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Introduction
The oncogene RET is involved in recurrent chromosomal
rearrangements found in thyroid and more recently in lung
cancer [1–4]. In thyroid cells, it rearranges with various genes
in a class of rearrangements known as RET/PTC
rearrangements, which are known to be carcinogenic for
thyroid cells and result in development of papillary thyroid
carcinoma (PTC) [5]. The incidence of thyroid cancer has
steadily increased over the past several decades; in the United
States alone, cases have doubled in the past decade and
nearly tripled since the early 1970s [6,7]. Interestingly, the
increase in thyroid cancer is almost entirely attributable to an
increase in PTC [7]. Approximately 20% of all PTC cases are
due to RET/PTC rearrangements [5]. The most common form
of RET/PTC rearrangement is the RET/PTC1 type, where RET
translocates with CCDC6 [8]. RET and CCDC6 are both
located within common chromosomal fragile sites, FRA10G
and FRA10C, respectively. Recently we found that the
formation of RET/PTC1 rearrangements can be induced in
human thyroid cells through treatment with fragile site-inducing
chemicals [9]. Therefore, it is conceivable that exposure to
chemicals that can induce fragile sites may contribute to the
increasing rates of thyroid cancer.
Chromosomal fragile sites are specific regions of the
genome that exhibit gaps or breaks on metaphase
chromosomes under conditions that partially inhibit DNA
replication [10]. These sites often co-localize with regions
deleted, amplified, or rearranged in cancer [11]. Over half of all
known simple recurrent chromosomal translocations in cancer
have breakpoints located within at least one fragile site [12].
Mutational signatures of some unexplained homozygous
deletions in cancer cell lines match those found in fragile site
regions [13]. Furthermore, fragile site-inducing conditions
introduced in vivo deletions within the tumor suppressor gene
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FHIT and generated oncogenic RET/PTC1 rearrangements
similar to those in patients [9,14].
Although a strong connection between fragile sites and
cancer has been established, little is known about the initial
events leading to DNA breakage at these sites. Chromosomal
fragile sites are traditionally defined cytogenetically as
unstained gaps with an average size of 3 Mb. Some common
fragile sites have been defined on the molecular level, where
DNA breakage is observed over large regions up to several
megabases in size [15]. Unlike rare fragile sites, which consist
of repeated sequence elements present in less than 5% of the
population and inherited in a Mendelian manner [16], common
fragile sites are present in all individuals and have no known
consensus sequence [17]. Common fragile sites are further
characterized based on the culture conditions known to induce
breakage within these regions, the most common being
aphidicolin (APH), an inhibitor of DNA polymerases α, β, and δ
[18,19]. Although no consensus sequence is known for
common fragile sites, several characteristics are shared among
many sites studied to date, including being late-replicating
[20–23], located within large genes [10], containing highly
flexible AT-rich sequences [24,25], and having the potential to
form highly stable DNA secondary structures [25–27].
Recently, in studying of the human chromosome 10 sequence,
we found that APH-induced common fragile sites are predicted
to form more stable DNA secondary structures that cluster with
greater density than non-fragile regions [28]. One proposed
mechanism for common fragile site breakage is that replication
stress results in a long stretch of single-stranded DNA and
subsequent formation of stable DNA secondary structures,
which can pause polymerase progression, resulting in
incomplete replication at fragile sites and ultimately DNA
breakage [10]. In addition to DNA replication, transcription of
large genes at fragile sites can result in the formation of stable
R-loop structures that ultimately result in common fragile site
breakage [29]. Triplet repeat expansions, including those
observed at rare fragile sites, also form stable R-loops during
transcription, most likely influenced by the formation of stable
DNA secondary structures on the non-template strand [30–32].
DNA topoisomerases play a critical role in maintaining
chromosome structural integrity during DNA processes such as
replication or transcription by regulating DNA supercoiling and
removing knots in the genomic material [33]. During replication
and transcription, topoisomerase I alleviates DNA supercoiling
by transiently inducing a single-strand DNA break and then re-
ligating at the cleavage site. Topoisomerase IIα modulates
DNA supercoiling and removes knots and tangles in the DNA
formed during replication by transiently inducing a double-
strand DNA break and then re-ligating at the cleavage site.
Additionally, DNA topoisomerases I and II can recognize and
preferentially cleave DNA at regions capable of forming stable
DNA secondary structures [34–36], similar to those predicted
or formed at fragile sites. Furthermore, normal topoisomerase I
activity is vital for common fragile site breakage [37,38].
The critical role of DNA topoisomerases in replication and
transcription, their recognition of DNA secondary structures,
and the involvement of topoisomerase I in fragile site breakage,
prompted us to directly investigate the role of these enzymes in
initiating common fragile site breakage. The nucleotide
locations of APH-induced DNA breaks within intron 11 of the
RET oncogene, the major breakpoint cluster region in patients
with PTC [39], were determined using ligation-mediated PCR
(LM-PCR) and were at or near topoisomerase I and/or II
predicted DNA cleavage sites. Furthermore, using DNA
secondary structure predictions of the intron 11 sequence, the
APH-induced breakpoints were present in structural features
known to be recognized by topoisomerases I and II. Finally,
treatment of thyroid cells with low doses of topoisomerase
catalytic inhibitors significantly reduced the rate of APH-
induced DNA breakage within intron 11 of RET, as well as
intron 4 of FHIT, located within the most active common fragile
site FRA3B, to levels observed in untreated samples. These
results support the involvement of DNA topoisomerases I and II
in the initiation of DNA breakage at APH-induced common
fragile sites, possibly through recognition of DNA secondary
structures formed during perturbed DNA replication.
Materials and Methods
Cell line and culture conditions
Experiments were performed on HTori-3 cells, a human
thyroid epithelial cell line transfected with an origin-defective
SV40 genome. They are characterized as immortalized,
partially transformed, differentiated cells having three copies of
chromosome 10 with intact RET loci and preserve expression
of thyroid differentiation markers such as thyroglobulin
production and sodium iodide symporter [40]. They also
contain one copy of chromosome 3, and four copies of
chromosome 12. The cells were purchased from the European
Tissue Culture Collection and grown in RPMI 1640 medium
(Invitrogen) supplemented with 10% fetal bovine serum.
Cell treatments and fragile site induction
For breakpoint detection, HTori-3 cells (1x105) were plated in
6-well plates and treated 18 hours later for 24 hours with 0.4
µM APH, in the presence or absence of 3 µM merbarone, 6 nM
betulinic acid (BA), or 150 nM CPT-11 (all from Sigma). For
detection of DNA topoisomerase I and II cleavage sites,
HTori-3 cells were plated in the same manner, and treated for
1.5 hours with either 10 µM CPT-11 or 10 µM VP-16 (Sigma).
DNA breaks were directly introduced to HTori-3 genomic
DNA through digestion with the restriction enzyme BanI or XbaI
(New England BioLabs). DNA breaks were induced within
intact nuclei isolated from HTori-3 cells [isolation of nuclei was
performed as described in [41]] through treatment with BanI,
after which the genomic DNA was isolated.
DNA breakpoint mapping by LM-PCR
DNA breaks were identified within intron 11 of RET using
four sets of primers (Table S1), two sets detecting breaks on
one DNA strand and two sets detecting breaks on the
complementary strand, and each set covering a DNA region of
approximately one Kb. Each primer set consists of a 5’-
biotinlyated primer that extends to the breakpoint, and two
nested primers, used separately in the first and second rounds
DNA Topoisomerases in RET Fragility
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of PCR to amplify the DNA. DNA breaks within FRA3B were
isolated using a set of primers corresponding to intron 4 of
FHIT (Table S1) [9], which is a hotspot of APH-induced DNA
breakage in FRA3B [40,42]. The primers: 12p12.3-1, -2 and -3
[9] were used to detect DNA breaks within a non-fragile region,
12p12.3 [25].
Detection of DNA breakpoints following drug treatment was
performed as previously described with modifications [9].
Briefly, genomic DNA was isolated from HTori-3 cells with or
without treatment. Primer extension was performed using 200
ng of DNA at 45°C with DNA Sequenase (Affymetrix, Inc.), and
the DNA breaks were isolated through ligation of the LL3/LP2
linker, and then using streptavidin beads. The ligation
conditions known to favor blunt-ended DNA ligation were used
[43], with lower ATP concentrations (50 µM) and the addition of
hexamminecobalt chloride (1.5 µM). Amplification of these DNA
breaks was achieved by nested PCR of the extension-ligation
products, using the equivalent of 8 ng of genomic DNA per
reaction (for all treatments except APH + CPT-11, where 4 ng
was used). The final PCR products were resolved by
electrophoresis on a 1.3% agarose gel. Each band observed
on the gel corresponds to a break isolated within the 1 kb
region of interest. Each experimental replicates includes 6 LM-
PCR reactions (48 ng genomic DNA), and breakage frequency
is referred as DNA breaks per 100 ng DNA per gene locus.
More than three experimental replicates (specified in the figure
legends) were performed for each treatment. The starting
material for each replicate was obtained from a separate cell
treatment. The size of the bands observed was confirmed by
DNA sequencing. The nucleotide location of the breakpoints
was determined from the sequencing results by identifying the
nucleotide adjacent to the LL3/LP2 linker sequence.
DNA secondary structure prediction by Mfold
The DNA sequence of intron 11 of RET was obtained from
NCBI (human genome build 37.2, Chr10:
43610185-43612031). Using the Mfold program [44], the
potential of single-stranded DNA to form stable secondary
structures can be predicted. The secondary structure forming
potential of RET intron 11 was analyzed by inputting 300-nt
segments with 150-nt shift increments into the Mfold program.
We choose the 300-nt length because it equals the length of an
Okazaki initiation zone of the DNA replication fork in
mammalian cells, which possesses a single-stranded property
during DNA replication [45,46]. The default [Na+], [Mg2+], and
temperature used were 1.0 M, 0.0 M, and 37°C, respectively.
The most stable predicted DNA secondary structure for each
300-nt segment was used to analyze the location of APH-
induced DNA breaks within intron 11 of RET.
Cell survival analysis following drug treatment
To analyze cell viability, HTori-3 cells (1x105) were plated in
6-well plates and treated 18 hours later with 0.4 µM APH in the
presence or absence of topoisomerase inhibitors for 24 hours.
Cell were harvested by trypsinization, washed with phosphate-
buffered saline (PBS, Invitrogen), and re-suspended in PBS
containing 2 µg/mL propidium iodide. Cell viability was then
determined using a Becton Dickinson FACSCalibur flow
cytometer. Titrations of betulinic acid (3 nM to 3 µM),
merbarone (1 to 100 µM), and CPT 11 (3 nM to 10 µM) were
performed to determine optimal dosages in HTori-3 cells. After
determining an optimal range of doses for each topoisomerase
inhibitor alone, titrations were also performed for betulinic acid
(3 nM to 0.3 µM), merbarone (1 to 10 µM), and CPT 11 (150 to
500 nM) in combination with 0.4 µM APH.
To analyze active apoptosis, HTori-3 cells (1x105) were
plated, treated and trypsinized as described above. Cells were
then washed with PBS, and re-suspended in 1X Annexin V
binding buffer. Annexin V stain (BD Biosciences) was then
added to each sample and incubated for 15 minutes. Early
apoptotic cells were quantified using a BD Accuri C6 flow
cytometer.
HTori-3 cells (1x105) were quantified using a hemocytometer
and plated in 6-well plates. Cells were then treated, harvested
as above and re-plated in fresh media. Cells were quantified
using a hemocytometer while re-plating and after cells had
been allowed to recover for an additional 24 hours in chemical-
free media.
To determine the distribution of cells in each phase of the
cell cycle, HTori-3 cells (2x105) were treated as above, washed
with PBS, and re-suspended in 100% cold ethanol, while gently
vortexing. Cells were incubated overnight, and then washed
and resuspended in PBS containing 50 µg/mL propidium iodide
and 100 µg/mL RNase. The cell cycle profile was analyzed
using a BD Accuri C6 flow cytometer, and ModFit LT (Verity
Software House) was used to determine the percentage of
cells in each cell cycle phase.
Statistical analysis
All data are presented as the mean ± standard derivation
(SD) or as a percentage. All statistical analyses were
performed using two-tailed Student’s t-test.
Results
Identification of APH-Induced DNA Breakpoints Within
Intron 11 of RET
To investigate the initial events of fragile site-induced DNA
breakage, the nucleotide location of APH-induced DNA
breakpoints within intron 11 of RET was identified by LM-PCR.
The translocation of RET with various partner genes is the
hallmark of RET/PTC rearrangements, and the major
breakpoint cluster regions observed in patients occur within
intron 11 [39]. Previously, we established using LM-PCR that
APH treatment induces DNA breakage within intron 11 of RET
in the human thyroid epithelial cell line HTori-3, and this
breakage is specific to fragile sites [9]. Here, the entire RET
intron 11 was examined by the same method for APH-induced
breakpoints using genomic DNA isolated from HTori-3 cells
following treatment with 0.4 µM APH for 24 hours. In short, the
genomic DNA was subjected to primer extension using
biotinylated primers specific for the region of interest (see
Materials and Methods; Table S1).
Upon reaching a DNA break, the synthesis reaction
terminates, resulting in a blunt-ended DNA molecule, which
was then captured by linker ligation. The linker-attached DNAs
DNA Topoisomerases in RET Fragility
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were isolated using streptavidin beads, amplified by two rounds
of nested PCR, and visualized by agarose gel electrophoresis
(Figure 1). Each lane on the agarose gel represents DNA
isolated from approximately 1300 cells and each band on the
gel represents a DNA break isolated within RET intron 11. A
total of 144 DNA breaks were isolated within the 1847-bp intron
11 sequence of RET on both DNA strands using four sets of
primers, sets 1-4 (Figure 1B; Table S2). DNA breakage within
RET intron 11 was observed at a frequency of 4.08 ± 1.50 DNA
breaks per 100 ng genomic DNA per 1kb locus, significantly
more than the rate of DNA breakage without treatment (0.9 ±
0.50 breaks/100 ng DNA/locus, P = 2.50E-4, using a two-tailed
Student’s t-test; Table 1, Figure 1A).
To assure the location of the APH-induced breakpoints
representing the initial events of APH-induced fragile site
breakage within this region, we first tested that the LM-PCR
procedure could accurately identify the nucleotide location of a
DNA break, and that the breaks being detected were not due to
premature termination of the primer extension reaction.
Genomic DNA isolated from HTori-3 cells was digested with
either the restriction enzyme BanI or XbaI. The LM-PCR
products from the RET primer set 1 (Table S1) were expected
to be 454 bp and 864 bp in size, respectively, for BanI and
XbaI digested DNAs (Figure 2A). PCR products corresponding
to the correct sizes were observed for the digested DNA
samples, and DNA sequencing revealed that 100% of the BanI
or XbaI-induced breaks corresponded to the correct nucleotide
location (data not shown). These results verify that LM-PCR is
a valid method for identification of DNA breakpoints up to about
1Kb from the initial biotinylated primer.
Next, we examined whether the locations of DNA breaks
being detected by LM-PCR reflect true APH-induced breaks,
not the consequences of subsequent repair processes or DNA
purification procedures. Intact HTori-3 nuclei were treated with
Table 1. Frequency of DNA breakage at RET intron 11,
FRA3B, and non-fragile 12p12.3 as detected by LM-PCR.
 DNA Breaks/100 ng DNA/Locus (±SD)
Treatment RET FRA3B 12p12.3
Untreated 0.90 ± 0.50 3.75 ± 0.93 0.13 ± 0.26
0.4 µM APH 4.08 ± 1.50 18.40 ± 2.04 0.13 ± 0.26
0.4 µM APH + 6 nM BA 1.25 ± 0.58 3.75 ± 1.74 -
0.4 µM APH + 3 µM Merbarone 0.97 ± 0.38 5.00 ± 2.80 -
0.4 µM APH + 150 nM CPT11 23.06 ± 3.75 36.98 ± 9.56 1.17 ± 0.50
doi: 10.1371/journal.pone.0075741.t001
Figure 1.  LM-PCR detection of DNA breaks within intron 11 of RET.  DNA breaks formed in intron 11 of RET were detected by
LM-PCR without treatment (A) or following 24-hour treatment with 0.4 µM APH alone (B) or in combination with the DNA
topoisomerase I and II catalytic inhibitors 6 nM betulinic acid (C) or 3 µM merbarone (D). Representative gels are shown. Each lane
represents a separate PCR reaction using DNA from approximately 1300 cells. The first lane of each gel is a 100-bp molecular
weight ladder.
doi: 10.1371/journal.pone.0075741.g001
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Figure 2.  Location of APH-induced DNA breakpoints within intron 11 of RET detected by LM-PCR.  (A) The location of 144
APH-induced DNA breakpoints isolated within intron 11 of RET by LM-PCR were determined by DNA sequencing (arrowheads).
DNA breaks identified on the strand shown by the sequence are indicated by black arrowheads, and on the complementary strand
by grey arrowheads. Open arrowheads indicate the locations of known patient breakpoints observed in PTC tumors containing
RET/PTC rearrangements [39,47–50]. The location of BanI and XbaI digestion sites within intron 11 are labeled. RET primer sets
(see Table S1) are indicated by arrows. Lines with circles are dual biotin-labeled primers followed by two nested primers. The
dashed black lines represent primer set 1, dashed grey lines primer set 2, solid black lines primer set 3, and solid grey lines primer
set 4. The sequence of intron 11 is displayed along with the flanking exon 10 and 11 sequences, shown in italics. (B) The
distribution of APH-induced DNA breakpoints within intron 11 are depicted as a smooth curve fit of the percentage of breakpoints (y
axis) located every 50 bp of intron 11 in a 5’ to 3’ direction (x axis).
doi: 10.1371/journal.pone.0075741.g002
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BanI, after which genomic DNA was isolated and analyzed by
LM-PCR using RET primer set 1. After DNA sequencing of 28
breakpoints generated by the LM-PCR, 79% of breakpoints
located to the predicted nucleotide, while the remaining
breakpoints contained deletions up to 5 bp, which may be the
result of exonuclease digestion (data not shown). Together,
these results show that the nucleotide locations of DNA breaks
identified by LM-PCR mostly correspond to the initially induced
breaks formed inside the cell.
The nucleotide location of the 144 APH-induced DNA
breakpoints was determined by sequencing of the PCR
products. APH treatment induced DNA breakage throughout
intron 11 on both DNA strands (Figure 2A). Interestingly, the
breakpoints formed a notable pattern of clusters at
approximately every 250 bp, equivalent to spacing between
nucleosomes (Figure 2B). Next, the locations of the APH-
induced breakpoints were compared with the location of known
breakpoints found in PTC tumors containing RET/PTC
rearrangements (Figure 2A; Figure S1, Table S2) [39,47–50].
We found that 81 (58%) of the APH-induced breakpoints had a
known patient breakpoint located within 0 to 20 bp. While the
locations of breakpoints identified in PTC tumors were isolated
following rearrangement, the APH-induced breakpoints were
determined before a translocation event. In most PTC tumors,
small insertions or deletions ranging from 1 to 18 bp have been
observed surrounding the fusion points.
These results reveal that APH treatment induces DNA
breakage throughout intron 11 of RET, and that many of these
breakpoints are located at or near breakpoints found in tumors
from patients. We also show that the LM-PCR can accurately
identify the nucleotide location of a DNA breakpoint. Therefore,
the locations of these breakpoints can be used to identify initial
events in APH-induced fragile site breakage within the RET
oncogene.
Location of APH-induced DNA Breakpoints Relative to
Predicted Topoisomerase I and IIα Cleavage Sites
To determine if DNA topoisomerases I and IIα are involved in
initiating APH-induced DNA breaks, 144 APH-induced DNA
breakpoints were compared to predicted topoisomerase I and
IIα cleavage sites. The location of topoisomerase I cleavage
sites within RET intron 11 were predicted on both DNA strands
using the consensus sequence determined by Been et al. [51].
All APH-induced breakpoints were located within 19 bp of a
predicted topoisomerase I site, with 76% being within 6 bp
(Figure 3A; Table S2). As with topoisomerase I, topoisomerase
IIα cleavage sites were predicted within RET intron 11 on both
strands using the consensus sequence [52] and compared to
the APH-induced DNA breaks. All APH-induced breakpoints
had a topoisomerase IIα site within 12 bp, with 91% being
within 6 bp (Figure 3B; Table S2).
Since the topoisomerase I and IIα consensus sequences are
not strictly recognized, we wanted to verify that these enzymes
cleave DNA within RET intron 11 and that these cleavage sites
correspond with the predicted sites. To capture topoisomerase
breakage, HTori-3 cells were treated with the topoisomerase
poisons CPT 11 and VP-16, which allow topoisomerases I and
II, respectively, to cleave DNA but prevent re-ligation [53,54].
HTori-3 cells were exposed to 10 µM CPT-11 or VP-16 for 1.5
hours, treatments known to induce detectable levels of
topoisomerase DNA breakage [55,56], after which the DNA
was isolated and analyzed for DNA breakage within RET intron
11 by LM-PCR using primer set 1. Break frequencies for CPT
11 and VP-16 treated cells were 1.97±1.40 and 1.62 ± 1.20
DNA breaks/100 ng DNA/locus, respectively. A total of 22
breakpoints were sequenced for CPTs 11 and 21 for VP-16
and compared to predicted topoisomerase I or IIα cleavage
sites, respectively. Interestingly, 18% of the CPT 11-induced
and 29% of the VP-16-induced breakpoints corresponded to a
predicted cleavage site (Figure 4). The remaining breakpoints
were located within 6 bp of a predicted topoisomerase I or IIα
site, suggesting the consensus sequences are not a perfect
predictor of topoisomerase breakage.
If we use the criterion set forth by the topoisomerase poisons
of being at or within 6 bp of a predicted topoisomerase I or IIα
cleavage site, topoisomerase breakage can explain all but one
of the APH-induced breakpoints observed. Specifically, 8% are
associated with topoisomerase I, 24% with topoisomerase IIα,
and 67% with both topoisomerase I and IIα. Together, these
results suggest the potential involvement of DNA
topoisomerases I and IIα in the initiation of fragile site breakage
within RET intron 11 following treatment with APH.
Comparison of APH-Induced DNA Breakpoints to Sites
of Predicted DNA Secondary Structures with
Topoisomerase Cleavage Features.  Aside from the
recognition of consensus sequences in double-stranded DNA,
DNA topoisomerases I and II recognize and preferentially
cleave single-stranded DNA within regions that form DNA
secondary structures. DNA topoisomerase I cleavage of single-
stranded DNA requires the formation of a DNA duplex, where
cleavage occurs within the duplexed stem of the secondary
structure, and the consensus sequence needs only to be
approximate [34]. DNA topoisomerase II cleaves DNA hairpins
one nucleotide from the 3’-base of the stem, where DNA
secondary structure and the presence of a double-stranded/
single-stranded DNA junction at the 3’-base of the hairpin,
rather than sequence specificity, are the predominant features
recognized by the enzyme [35]. Additionally, human
topoisomerase IIα recognizes hairpin structures formed within
alpha satellite DNA, and cleaves within the single-stranded
DNA loop region of the hairpin structure [36]. Recently, using
DNA secondary structure-forming analyses, we predicted
potential fragile sites on chromosome 10, and among these
regions was the RET oncogene, including intron 11 [28]. Using
an in vitro reduplexing assay, we showed that RET intron 11
DNA forms significantly greater levels of DNA secondary
structure than regions not predicted to possess this ability.
Therefore, to examine correlations between the location of
the APH-induced DNA breakpoints and DNA secondary
structure formation, potential DNA secondary structures for
both DNA strands of RET intron 11 were predicted using the
program Mfold, analyzing 300-nt segments with 150-nt shift
increments and determining the structure with the most
favorable free energy value for each DNA segment. Due to the
sequence overlap from the segment shift, the location of each
DNA breakpoint was analyzed on two potential structures and
DNA Topoisomerases in RET Fragility
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Figure 3.  Comparison of 144 APH-induced DNA breakpoints to predicted DNA topoisomerase I and II cleavage sites.  (A)
Topoisomerase I cleavage sites within RET intron 11 were predicted based on the consensus [5’-(A/T/G) (C/G/A) (A/T) (T/C)-3’]
immediately upstream of the cleavage site [51], compared to APH-induced DNA breakpoints, and represented as the distance in bp
from each APH breakpoint to the closest predicted cleavage site (x axis). A positive distance refers to the closest topoisomase I
cleavage site being downstream of the APH breakpoint, and a negative distance being upstream. The percentage of all APH-
induced breakpoints is displayed on the y axis. (B) Topoisomerase IIα cleavage sites were predicted using the consensus sequence
[5’-(no A) (no T) (A/no C) (-) (C/no A) (-) (-) (-) (-) (no T) (-) (T/no G) (C/ no A) (-)-3’] [52], where breakage occurs between the
nucleotides five and six. The locations of APH-induced breakpoints were compared to the predicted sites and represented in the
same manner as in (A).
doi: 10.1371/journal.pone.0075741.g003
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assigned one structural feature for each breakpoint (Figure 5A;
Table S3). Of the 144 APH-induced DNA breakpoints, 61
(42.4%) are located within a predicted double-stranded DNA
stem, suggesting the potential involvement of DNA
topoisomerase I (Figure 5B). Another 49 breakpoints (34%) are
located at a double-stranded/single-stranded DNA junction,
and 22 breakpoints (15.3%) are located within a single-
stranded DNA loop, suggesting the involvement of DNA
topoisomerase II. The remaining 12 breakpoints (8.3%) are
located in predicted single-stranded DNA bubbles, which at this
time lack a known potential mechanism for DNA cleavage.
These findings provide additional support for the role of DNA
topoisomerases I and II in the initiation of APH-induced fragile
site breakage within RET intron 11. Furthermore, they suggest
a mechanistic connection between the formation of DNA
secondary structures at fragile sites and the initial DNA
breakage events following APH treatment.
Topoisomerase Catalytic Inhibitors Decrease APH-
Induced DNA Breakage at RET.  Since the locations of the
APH-induced DNA breakpoints within RET intron 11 suggest
the potential involvement of topoisomerases I and II in initiating
DNA breakage within this region following APH treatment, this
hypothesis was directly tested by examining the effect on DNA
breakage frequency in HTori-3 cells co-treated with APH and
topoisomerase catalytic inhibitors. Topoisomerase catalytic
inhibitors block DNA cleavage by the enzyme; therefore, if
topoisomerases participate in initiating APH-induced DNA
breakage within RET intron 11, the catalytic inhibitors would be
expected to decrease the rate of APH-induced DNA breakage
within this region. Two catalytic inhibitors, betulinic acid and
merbarone, were chosen for cell treatments. Betulinic acid (BA)
inhibits topoisomerase I DNA cleavage through prevention of
topoisomerase I-DNA cleavable complex formation by
sequestering topoisomerase I in the nucleoplasm [57]. There
have been conflicting reports over the inhibitory effect of BA on
topoisomerase IIα [58–60], and no systematic study has been
performed to clarify the action of the drug on this enzyme.
Merbarone, an inhibitor of DNA topoisomerase II with
selectivity for the α over the β isoform [61], inhibits
Figure 4.  Comparison of CPT 11- and VP-16- induced topoisomerase I and II cleavage to predicted cleavage
sites.  Topoisomerase I and II DNA cleavage was induced by treatment of HTori-3 cells with 10 µM CPT-11 or VP-16, respectively,
for 1.5 hours. The location of CPT 11- (n=22) or VP-16- (n=21) induced DNA cleavage within RET intron 11 was detected using LM-
PCR and RET primer set 1 and compared to either topoisomerase I (CPT 11) or II (VP-16) predicted cleavage sites. A positive
distance indicates the predicted cleavage site is downstream of the drug-induced site, and a negative distance indicates the
predicted cleavage site is upstream. The percentage of all drug-induced breakpoints is represented on the y axis.
doi: 10.1371/journal.pone.0075741.g004
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Figure 5.  Location of 144 APH-induced RET intron 11 breakpoints on predicted DNA secondary structures.  (A) A
representative predicted DNA secondary structure is shown, corresponding to the RET gene nucleotides 43,610,735 to 43,611,034
(hg37.2), with the locations of APH-induced breakpoints indicated by arrows. The program Mfold was used to predict potential DNA
secondary structures within the RET intron 11 sequence, by analyzing 300-nt fragments one at a time with a 150-nt shift increment
on both DNA strands, and selecting the most energetically favorable structure for each fragment. The location of each APH-induced
DNA breakpoint on the predicted secondary structures was analyzed. (B) The percentage of the APH-induced RET breakpoints is
shown for each DNA secondary structural features recognized by the DNA topoisomerases I and II.
doi: 10.1371/journal.pone.0075741.g005
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topoisomerase IIα by interacting with the enzyme and
preventing DNA scission [62].
Optimal dosages of BA or merbarone were determined in
combination with APH treatment in HTori-3 cells, such that
significant levels of cell death were not induced and cells were
able to replicate their DNA (Figure S2). The cell cycle profile of
the cells treated with the combination of chemicals shows a
similar pattern as that for aphidicolin treatment alone (Figure
S2D). Using these established conditions, HTori-3 cells were
treated with 0.4 µM APH and 6 nM BA or 3 µM merbarone for
24 hours. The genomic DNA was then isolated and breakpoint
analysis was performed by LM-PCR using RET primer set 1
(Figure 6A). Co-treatment of cells with APH and BA or
merbarone significantly decreased the level of APH-induced
DNA breakage within RET intron 11 (1.25 ± 0.58 or 0.97 ± 0.38
breaks/100 ng DNA/locus, P = 3.34E-3 or 1.53E-3,
respectively, two-tailed Student’s t-test), to levels similar to
untreated cells (Figure 6A, Table 1).
Next, the involvement of topoisomerases I and IIα in APH-
induced fragile site breakage at the most active common fragile
site, FRA3B, was tested by determining the rate of DNA
breakage within intron 4 of FHIT, a region within FRA3B known
to exhibit clustering of APH-induced DNA breakage [41,42]. We
previously established that APH treatment in HTori-3 cells
results in DNA breakage within this region [9]. In agreement
with our previous results, a significant increase in DNA
breakage was observed within FRA3B following treatment of
HTori-3 cells with 0.4 µM APH for 24 hours (18.40 ± 2.04
breaks/100 ng DNA/locus) compared to untreated (3.75 ± 0.93
breaks/100 ng DNA/locus, P = 1.36E-7, two-tailed Student’s t-
test; Figure 5C). As was seen in intron 11 of RET, when APH
treatment was combined with BA or merbarone, the rate of
APH-induced DNA breakage significantly decreased (3.75 ±
1.74 or 5.00 ± 2.80 breaks/100 ng DNA/locus, P = 5.03E-7 or
7.21E-6, respectively, two-tailed Student’s t-test) to levels
similar to untreated cells (Figure 6B). Together, these results
confirm that DNA topoisomerases I and IIα are involved in
initiating APH-induced DNA breakage within common fragile
sites located at RET and FHIT, and this mechanism may
extend to other APH-induced common fragile sites as well.
Discussion
In this study, we analyzed the initial events of APH-induced
common fragile site breakage within the RET oncogene. APH
treatment of HTori-3 cells induces significant levels of DNA
breakage within intron 11 of RET, the breakpoint cluster region
found in PTC patients. Previously, we confirmed that APH
treatment specifically induces breakage at fragile sites in
HTori-3 cells by detecting high levels of breakage within RET
and FHIT, in APH-induced common fragile sites FRA10G and
FRA3B, respectively, but not in the non-fragile 12p12.3 region
and G6PD gene, located within the non-APH inducible rare
folate-sensitive fragile sites FRAXF [9]. Using LM-PCR, here
we mapped the nucleotide location 144 APH-induced DNA
breaks on both strands of RET intron 11. All but one of the
breakpoints induced by APH were located at or near predicted
DNA topoisomerase I and/or IIα cleavage sites (Table S2).
Utilizing the DNA secondary structure prediction program
Mfold, the locations of these APH-induced breakpoints were
compared to predicted DNA secondary structures of the intron
11 sequence. Most breakpoints (91.7%) were located at
structural features known to be recognized and preferentially
cleaved by topoisomerases I or II (Figure 3). Finally, we
confirmed the involvement of topoisomerases I and IIα in APH-
induced DNA breakage at the RET oncogene by measuring the
effect of topoisomerase catalytic inhibitors on the level of APH-
induced DNA breakage within intron 11. When catalytic
inhibitors BA and merbarone were combined with APH
treatment, the frequency of DNA breakage within RET intron 11
significantly decreased to levels similar to untreated cells.
Furthermore, this effect was also observed at FHIT intron 4,
confirming the involvement of DNA topoisomerases I and IIα in
APH-induced DNA breakage at other common fragile sites as
well. Together, these results provide strong evidence that DNA
topoisomerases I and IIα have a role in initiating APH-induced
DNA breakage at common fragile sites, through recognition
and preferential cleavage of DNA secondary structures.
Previous studies have also implicated DNA topoisomerase I
in common fragile site instability. Depletion of topoisomerase I
in HCT116 cells significantly increases common fragile site
breakage [38]. Arlt et al. observed that co-treatment of cells
with APH and the topoisomerase I catalytic inhibitor BA
significantly decreased common fragile site breakage, including
FRA3B [37]. These results are consistent with our observation
that BA significantly decreased APH-induced DNA breakage at
RET (FRA10G) and FHIT (FRA3B) (Figure 6). When Arlt et al.
combined APH treatment with the topoisomerase I poison
camptothecin (CPT), which prevents topoisomerase I from re-
ligating DNA following cleavage, they also observed a
significant reduction in common fragile site breakage, including
FRA3B [37]. However, when we combined a low dosage (150
nM) of the topoisomerase poison CPT 11 with 0.4 µM APH
treatment, we observed a significant increase in APH-induced
DNA breakage at RET (FRA10G) and FHIT (FRA3B) in HTori-3
cells (Figure 7). The differences between our observations and
those of Arlt et al. may be attributed to detection methods. We
have detected fragile site breakage as single and double strand
DNA breaks, while Arlt et al. have detected chromosomal
disruptions on metaphase chromosomes. Nevertheless, our
data combined with these previous studies provides compelling
evidence for DNA topoisomerase involvement in common
fragile site breakage.
One model for common fragile site expression is that
delayed replication can cause an uncoupling of the helicase
complex from the DNA polymerase, resulting in long stretches
of single-stranded DNA. Then, at fragile sites this DNA can
form stable DNA secondary structures that pause polymerase
progression and ultimately result in DNA breakage [10]. The
initial events of fragile site breakage remain unclear, but our
data here support the involvement of DNA topoisomerases I
and IIα in the initiation of APH-induced fragile site breakage.
DNA topoisomerases I and IIα participate in replication by
maintaining chromosomal structural integrity through transient
introduction of DNA breakage. Human topoisomerases I and
IIα have been observed at replication origins, and inhibition of
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Figure 6.  Effects of DNA topoisomerase catalytic inhibitors on the APH-induced common fragile site breakage.  (A) HTori-3
cells were treated with 0.4 µM APH in combination with the topoisomerase I and II catalytic inhibitors, 6 nM betulinic acid (BA) or 3
µM merbarone, for 24 hours. LM-PCR was used to detect DNA breaks within RET intron 11 using RET primer set 1. The frequency
of DNA breakage within RET intron 11 following 0.4 µM APH treatment combined with 6 nM betulinic acid or 3 µM merbarone
significantly decreases compared to APH treatment alone (*P ≤ 3.34E-3), to levels similar to untreated cells. (B) The frequency of
DNA breakage within FHIT intron 4, located within the APH-induced common fragile site FRA3B, shows a significant increase with
0.4 µM APH treatment. As with RET intron 11, the rate of APH-induced DNA breakage within FHIT intron 4 significantly decreased
when combined with BA or merbarone (*P ≤ 7.21E-6). All data were averaged from 5–7 replicated experiments. All statistical
analyses were performed using a two-tailed Student’s T-test. Error bars indicate standard deviations.
doi: 10.1371/journal.pone.0075741.g006
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topoisomerase I interferes with replication origin firing,
indicating these enzymes play a role in replication initiation
[63]. Once replication is initiated, DNA is unwound by DNA
helicase, resulting in DNA overwinding (positive supercoiling) in
front of the replication fork and DNA underwinding (negative
supercoiling) behind the replication fork. Positive and negative
supercoiling as a result of replication can be removed by both
topoisomerases I and IIα [64]. Negative supercoiling behind the
replication fork can also result in knots and tangles in the newly
replicated DNA, which can be removed by topoisomerase IIα
[65]. The presence of these enzymes at the replication fork,
their ability to cleave DNA, and their necessity for induction of
fragile site breakage at RET intron 11 and FHIT intron 4 in
HTori-3 cells following APH treatment all suggest these
enzymes are involved in the initiation of DNA breakage.
Furthermore, the location of APH-induced DNA breaks in RET
intron 11 at DNA secondary structural features recognized by
topoisomerases I and II suggests these enzymes may
recognize and preferentially cleave these structures while
following in front or behind the replication fork scanning for
topological changes, or may be recruited separately to these
sites.
As with DNA replication, transcription results in positive
supercoiling ahead of the transcription bubble and negative
supercoiling behind it [66,67]. Furthermore, negative
supercoiling enhances the formation of stable RNA-DNA
hybrids (R-loops) [68], which are associated with genomic
instability and double-strand DNA break formation [69]. Another
model for common fragile site breakage is that transcription of
long genes at fragile sites results in the formation of stable R-
loops due to the collision of transcription and replication
machinery, ultimately leading to genomic instability within these
regions [29]. DNA topoisomerase I activity is vital during
transcription for the removal of positive and negative
supercoiling, and thus suppressing R-loop formation [33].
Trinucleotide repeats, including those observed at rare fragile
sites, also preferentially form stable R-loops [30–32]. This may
be due to the formation of stable DNA secondary structures on
the non-template DNA strand [70]. Therefore, as with
replication, DNA secondary structure formation at common
Figure 7.  Rate of APH-induced DNA breakage in combination with CPT 11 treatment.  Co-treatment of HTori-3 cells with APH
and CPT 11 significantly increased the level of DNA breakage within RET intron 11 and FRA3B relative to APH treatment alone (*P
≤ 5.76E-4). This breakage was significantly greater than in the non-fragile 12p12.3 region ( # P ≤ 2.59E-5). The level of DNA
breakage for each treatment was measured using LM-PCR and averaged over at least three independent experiments. Significance
was calculated using a two-tailed Student’s T-test. Error bars represent standard deviations.
doi: 10.1371/journal.pone.0075741.g007
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fragile sites during transcription may result in the formation of
stable R-loops and stalled transcription machinery, which may
be recognized and preferentially cleaved by DNA
topoisomerase I.
RET protein expression in the thyroid is high in neural-crest
derived C-cells but not in follicular cells, where RET/PTC
rearrangements can result in its expression as a fusion protein
and lead to PTC. The HTori-3 cell line used in our study is
derived from normal human thyroid follicular epithelium [71]
and thus does not express RET, which we confirmed by RT-
PCR (data not shown). Since active transcription of a gene is
required for the transcription-associated model of common
fragile site breakage, delayed replication must be responsible
for all of the APH-induced fragile site breakage we detected at
the RET gene. Therefore, the formation of stable R-loops
cannot explain breakage at all common fragile sites, further
supporting the secondary structure-forming/replication-stalling
mechanism of common fragile site breakage.
Cancer is often treated with chemotherapeutic agents that
act as DNA topoisomerase poisons. The incidence of
secondary primary tumors is on the rise; in the United States,
they account for one in six of all newly diagnosed cancers [72],
which may be attributed to cancer treatments. Thyroid cancer
can occur after treatment of various cancers by chemotherapy,
including non-Hodgkin’s lymphoma [73,74] and testicular
cancer [75]. Specifically, PTC can occur as a second cancer
following treatment of osteosarcoma [76], rhabdomyosarcoma
[77], acute lymphoblastic leukemia, neuroblastoma, and
Ewing’s sarcoma [78–81] with chemotherapy alone. This
suggests that manipulation of normal topoisomerase activity
can result in PTC. Since we observe here that perturbed DNA
topoisomerase I and II activity can effect fragile site breakage
at the RET oncogene, more work should be done to investigate
the role of topoisomerase poisons and fragile sites in the
formation of secondary PTC tumors and other cancers.
These studies show that DNA topoisomerases I and II play a
vital role in initiating breakage at APH-induced common fragile
sites, providing valuable insight into the initial events of
common fragile site breakage. Furthermore, the mechanism by
which stable DNA secondary structures form at common fragile
sites during delayed replication is supported by our data, and
the idea that these structures can be recognized and
preferentially cleaved by topoisomerases is presented. Our
data provide new mechanistic insights regarding how fragile
site breakage at the RET oncogene can lead to generation of
carcinogenic rearrangements found in thyroid cancer. Since
RET rearrangements have also been found in lung cancer, this
mechanism may be of broad significance and involved in
generation of chromosomal rearrangements in other regions of
the genome and in multiple cancer types.
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